Susceptibility of HIV-2 to approved and experimental antiretroviral drugs: implications for treatment

被引：0
|
作者：
Witvrouw, M
Pannecouque, C
De Clercq, E
Switzer, WM
Folks, TM
Heneine, W
机构：
[1] Katholieke Univ Leuven, Rega Inst Med Res, Louvain, Belgium
[2] Ctr Dis Control & Prevent, Atlanta, GA USA
来源：
ANTIVIRAL THERAPY | 2002年 / 7卷
关键词：
D O I：
暂无
中图分类号：
R51 [传染病];
学科分类号：
100401 ;
摘要：
143
引用
收藏
页码：S155 / S155
页数：1
相关论文
共 50 条
  • [31] Transmitted drug resistance, selection of resistance mutations and moderate antiretroviral efficacy in HIV-2:: Analysis of the HIV-2 Belgium and Luxembourg database
    Ruelle, Jean
    Roman, Francois
    Vandenbroucke, Anne-Therese
    Lambert, Christine
    Fransen, Katrien
    Echahidi, Fedoua
    Pierard, Denis
    Verhofstede, Chris
    Van Laethem, Kristel
    Delforge, Marie-Luce
    Vaira, Dolores
    Schmit, Jean-Claude
    Goubau, Patrick
    BMC INFECTIOUS DISEASES, 2008, 8 (1)
  • [32] Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia, West Africa
    Togun, Toyin
    Peterson, Ingrid
    Jaffar, Shabbar
    Oko, Francis
    Okomo, Uduak
    Peterson, Kevin
    Jaye, Assan
    AIDS RESEARCH AND THERAPY, 2011, 8
  • [33] Polymorphism of HIV-2 integrase gene and in vitro phenotypic susceptibility of HIV-2 clinical isolates to integrase inhibitors:: raltegravir and evitegravir
    Roquebert, B.
    Damond, F.
    Collin, G.
    Matheron, S.
    Taieb, A.
    Peytavin, Ct
    Benard, A.
    Campa, P.
    Chene, G.
    Brun-Vezinet, F.
    Descamps, D.
    ANTIVIRAL THERAPY, 2007, 12 (05) : S92 - S92
  • [34] Polymorphism of HIV-2 integrase gene and in vitro phenotypic susceptibility of HIV-2 clinical isolates to integrase inhibitors:: raltegravir and evitegravir
    Roquebert, B.
    Damond, F.
    Collin, G.
    Matheron, S.
    Taieb, A.
    Peytavin, G.
    Bernard, A.
    Campa, P.
    Chene, G.
    Brun-Vezinet, F.
    Descamp, D.
    ANTIVIRAL THERAPY, 2007, 12 : S92 - S92
  • [35] HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro
    Roquebert, B.
    Damond, F.
    Collin, G.
    Matheron, S.
    Peytavin, G.
    Benard, A.
    Campa, P.
    Chene, G.
    Brun-Vezinet, F.
    Descamps, D.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 62 (05) : 914 - 920
  • [36] INACTIVATION OF HIV-2 BY SOLVENT DETERGENT TREATMENT
    PISZKIEWICZ, D
    TONDREAU, SC
    TRANSFUSION, 1990, 30 (02) : 192 - 192
  • [37] Novel agents for the treatment of HIV-2 infection
    Peterson, Kevin
    Rowland-Jones, Sarah
    ANTIVIRAL THERAPY, 2012, 17 (03) : 435 - 438
  • [38] Pre-treatment mortality and loss-to-follow-up in HIV-1, HIV-2 and HIV-1/HIV-2 dually infected patients eligible for antiretroviral therapy in The Gambia, West Africa
    Toyin Togun
    Ingrid Peterson
    Shabbar Jaffar
    Francis Oko
    Uduak Okomo
    Kevin Peterson
    Assan Jaye
    AIDS Research and Therapy, 8
  • [39] Clinical characteristics and antiretroviral treatment patterns in HIV-2 infected patients: Insights from a tertiary hospital in Portugal
    Rocha, R.
    Pineiro, C.
    Caldas, C.
    Santos, A. S.
    Serrao, R.
    Santos, L.
    HIV MEDICINE, 2023, 24 : 173 - 174
  • [40] Switching antiretroviral regimes for the treatment of HIV: safety implications
    Utrillo, Laia
    Vidal, Francesc
    Puig, Teresa
    Domingo, Pere
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (10) : 1349 - 1360
12345